0001144204-16-100010.txt : 20160509 0001144204-16-100010.hdr.sgml : 20160509 20160509173210 ACCESSION NUMBER: 0001144204-16-100010 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160509 DATE AS OF CHANGE: 20160509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 161632897 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 v437892_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-32587

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2726770
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Park Place, Suite 450, Annapolis, Maryland		21401
(Address of principal executive offices)		(Zip Code)

(410) 269-2600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer x

Non-Accelerated Filer ¨		Smaller Reporting Company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: The number of shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding as of May 1, 2016 was 65,591,840.

PHARMATHENE, INC.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION		1

Item 1. Unaudited Condensed Consolidated Financial Statements		1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16

Item 3. Quantitative and Qualitative Disclosures about Market Risk		22

Item 4. Controls and Procedures		22

PART II — OTHER INFORMATION		23

Item 1. Legal Proceedings		23

Item 1A. Risk Factors		24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		24

Item 3. Defaults Upon Senior Securities		24

Item 4. Mine Safety Disclosures		24

Item 5. Other Information		24

Item 6. Exhibits		25

Part I — FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2016			2015

ASSETS
Current assets:
Cash and cash equivalents	$	14,235,621		$	15,569,813
Billed accounts receivable		170,323			511,994
Unbilled accounts receivable		1,266,820			963,345
Prepaid expenses and other current assets		463,873			181,714
Total current assets		16,136,637			17,226,866

Property and equipment, net		196,143			233,694
Other long-term assets and deferred costs		53,384			53,384
Goodwill		2,348,453			2,348,453
Total assets	$	18,734,617		$	19,862,397

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	166,357		$	521,122
Accrued expenses and other liabilities		1,749,899			1,248,708
Accrued restructuring expenses - current		255,551			381,950
Other short-term liabilities		-			11,250
Current portion of derivative instruments		468,304			16,411
Total current liabilities		2,640,111			2,179,441

Accrued restructuring expenses - long term		43,809			108,641
Other long-term liabilities		424,213			433,407
Derivative instruments, less current portion		-			491,791
Total liabilities		3,108,133			3,213,280

Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,444,725 and 64,382,086 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively		6,444			6,438
Additional paid-in-capital		240,570,971			240,366,704
Accumulated deficit		(224,950,931	)		(223,724,025	)
Total stockholders' equity		15,626,484			16,649,117
Total liabilities and stockholders' equity	$	18,734,617		$	19,862,397

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended March 31,
	2016			2015

Contract revenue	$	1,005,694		$	7,068,746

Operating expenses:
Research and development		1,029,131			1,613,627
General and administrative		1,193,298			2,196,120
Restructuring expense		-			2,060,809
Depreciation		37,701			37,106
Total operating expenses		2,260,130			5,907,662

(Loss) income from operations	$	(1,254,436	)	$	1,161,084
Other income (expense):
Interest expense, net		(1,050	)		(25,325	)
Change in fair value of derivative instruments		39,898			338,245
Other income		4,119			9,196
Total other income		42,967			322,116

Net (loss) income before income taxes		(1,211,469	)		1,483,200
Income tax provision		(15,437	)		(19,805	)
Net (loss) income	$	(1,226,906	)	$	1,463,395

Basic net (loss) income per share	$	(0.02	)	$	0.02
Diluted net (loss) income per share	$	(0.02	)	$	0.02
Weighted average shares used in calculation of basic net (loss) income per share		64,404,396			63,633,290
Weighted average shares used in calculation of diluted net (loss) income per share		64,404,396			63,979,859

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

	Three months ended March 31,
	2016			2015

Net (loss) income	$	(1,226,906	)	$	1,463,395
Other comprehensive (loss) income:
Foreign currency translation adjustments		-			1,746
Comprehensive (loss) income	$	(1,226,906	)	$	1,465,141

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three months ended March 31,
	2016			2015

Operating activities
Net (loss) income	$	(1,226,906	)	$	1,463,395
Adjustments to reconcile (loss) income to net cash used in operating activities:
Share-based compensation expense		181,921			199,627
Change in fair value of derivative instruments		(39,898	)		(338,245	)
Depreciation expense		37,701			37,106
Deferred income taxes		15,437			19,805
Non-cash interest expense		5,485			10,933
Gain on the disposal of property and equipment		-			(7,600	)
Changes in operating assets and liabilities:
Billed accounts receivable		341,671			(5,863,332	)
Unbilled accounts receivable		(303,475	)		(296,828	)
Prepaid expenses and other current assets		(282,160	)		(253,779	)
Accounts payable		(354,765	)		146,740
Accrued restructuring expenses		(196,716	)		1,938,631
Accrued expenses and other liabilities		466,563			230,186
Net cash used in operating activities		(1,355,142	)		(2,713,361	)
Investing activities
Purchases of property and equipment		(150	)		(35,352	)
Proceeds from the sale of property and equipment		-			7,600
Net cash used in investing activities		(150	)		(27,752	)
Financing activities
Repayment of debt		-			(249,999	)
Net repayment of revolving credit agreement		-			-
Proceeds from issuance of common stock, net of offering costs		23,237			84,332
Other		(885	)		-
Net cash provided by (used in) financing activities		22,352			(165,667	)
Effects of exchange rates on cash		(1,252	)		(11,615	)
Decrease in cash and cash equivalents		(1,334,192	)		(2,918,395	)
Cash and cash equivalents, at beginning of period		15,569,813			18,643,351
Cash and cash equivalents, at end of period	$	14,235,621		$	15,724,956

Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	14,849

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2016

Note 1 - Business and Liquidity

We are a biodefense company engaged in developing two next generation anthrax vaccines. The next generation vaccines are intended to have more rapid time to protection, fewer doses for protection and less stringent requirements for temperature controlled storage and handling than the currently used vaccine.

Since 2006, we have been engaged in legal proceedings with SIGA Technologies, Inc. (“SIGA”). On December 23, 2015, the Delaware Supreme Court affirmed the Delaware Court of Chancery's judgment against SIGA which provides an estimated total award of approximately $208 million as of March 31, 2016 plus additional interest. On April 8, 2016, the Bankruptcy Court entered an order confirming SIGA’s third amended Reorganization Plan (the “Plan”) effective April 12, 2016 which provides for SIGA to emerge from bankruptcy and provides various alternatives for the final resolution of our litigation claim against SIGA during 2016. Under the Plan, we received an initial payment of $5 million from SIGA during April 2016 and during May 2016, received approximately $0.9 million, calculated by SIGA as interest on the judgment for the period of April 12, 2016 through April 30, 2016.

During the first half of 2015, we narrowed the scope of our product development programs, reduced our employee headcount and executed other cost reductions. These actions have allowed us to have sufficient cash to recognize the benefit of the SIGA award and advance our Anthrax vaccine programs without the need to raise additional capital. During the second half of 2015, we focused our efforts on creating alternatives for settling the SIGA litigation claim and developing business plans around possible outcomes.

During 2016, we will continue to develop our plans to create shareholder value from the alternative SIGA litigation outcomes and will commence execution of those plans.

On September 9, 2014, we signed a contract with the National Institutes of Allergy and Infectious Diseases (“NIAID") for the development of a next generation lyophilized anthrax vaccine based on our proprietary technology platform which contributes the recombinant protective antigen (“rPA”) bulk drug substance that is used in the liquid SparVax^® formulation. The contract is incrementally funded. Over the base period of the contract, we were awarded initial funding of approximately $5.2 million, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestones. NIAID exercised the first and second options under this agreement in September 2015 and December 2015, respectively. The exercised options provide additional funding of approximately $4.9 million and an extension of the period of performance through April 30, 2017. The contract has a total value of up to approximately $28.1 million, if all technical milestones are met and all eight contract options are exercised by NIAID. If NIAID exercises all options, the contract would last approximately five years. If NIAID does not exercise any additional options, the contract would expire by its terms on April 30, 2017.

As of March 31, 2016, our cash balance was $14.2 million, our accounts receivable (billed and unbilled) balance was $1.4 million, and our current liabilities were $2.6 million. We believe, based on the operating cash requirements and capital expenditures expected for 2016, the Company’s cash on hand at March 31, 2016 plus the $5 million initial payment received from SIGA during April 2016 and approximately $0.9 million, calculated by SIGA as interest, and received from SIGA during May 2016, is adequate to fund operations for at least the next twelve months.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC. We currently operate in one business segment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders’ equity. Transaction gains or losses are included in the determination of net loss.

In June 2015, we substantially liquidated PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income.

Cash and Cash Equivalents

Cash and cash equivalents are stated at market value which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.

Significant Customers and Accounts Receivable

Our primary customer is NIAID. As of March 31, 2016 and December 31, 2015, the Company’s receivable balances (both billed and unbilled) were comprised solely of receivables from NIAID.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2015 and determined that there was no impairment as of that date. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.

Accrued Restructuring Expense

Accrued restructuring expense as of March 31, 2016 is as follows:

	Balance as of						Balance as of
	December 31,		Paid		Amortized		March 31,
Description	2015		2016		2016		2016

Accrued severance expense	$	131,822	$	131,822	$	-	$	-
Accrued sublease expense		358,769		-		59,409		299,360
Total accrued restructuring expense	$	490,591	$	131,822	$	59,409	$	299,360

Fair Value of Financial Instruments

Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3- Fair Value Measurements for further details.

Revenue Recognition

We generate our revenue from cost-plus-fee contracts and in the past, have generated revenue from fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

Milestones are considered substantive if all of the following conditions are met:

•

it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

•

it relates solely to past performance, and

•

the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

Upon notice of termination of a contract from the government, all related termination costs are expensed. If there is assurance that collection is reasonably assured, then revenue is taken as if the contract was a cost-plus-fee contract.

Collaborative Arrangements

Even though most of our products are being developed in conjunction with support by the U.S. Government, we are an active participant in that development, with exposure to significant risks and rewards of commercialization relating to the development of these pipeline products. In collaborations where we are deemed to be the principal participant of the collaboration, we recognize costs and revenues generated from third parties using the gross basis of accounting; otherwise, we use the net basis of accounting. Cost paid to us by other collaborative arrangement members are recognized pursuant to their terms.

Research and Development

Research and development costs are expensed as incurred; up-front payments are deferred and expensed as performance occurs. Research and development costs include salaries, facilities expense, overhead expenses, material and supplies, preclinical expense, clinical trials and related clinical manufacturing expenses, share-based compensation expense, contract services and other outside services.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors and consultants under our stock compensation plans.

The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model, which considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.

The fair value of stock options granted to consultants is determined at the grant date using the Black-Scholes option pricing model and remeasured at each quarterly reporting date over their requisite service period. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.

The fair value of restricted stock grants granted to employees and non-employee directors is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

The fair value of restricted stock grants granted to consultants is determined based on the closing price of our common stock on the award date, is remeasured at each quarterly reporting date and is recognized as expense ratably over the requisite service period.

Employee share-based compensation expense recognized in the three months ended March 31, 2016 and 2015 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.

Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:

	Three months ended March 31,
	2016		2015

Research and development	$	29,293	$	60,735
General and administrative		152,633		192,633
Restructuring benefit		-		(53,741	)
Total share-based compensation expense	$	181,926	$	199,627

As a result of the restructuring and termination of employees, during the three months ended March 31, 2015, we recognized approximately $75,000 of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $129,000 of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $53,741 net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.

During the three months ended March 31, 2016, we made no stock option or restricted stock grants. During the three months ended March 31, 2015, we granted 12,000 options and made 117,500 shares of restricted stock grants to employees. At March 31, 2016, we had total unrecognized share-based compensation expense related to unvested awards of approximately $1.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 1.9 years.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of March 31, 2016, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.

Income tax expense was $0.02 million during each of the three months ended March 31, 2016 and 2015, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our consolidated balance sheets.

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potentially dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses. A total of approximately 6.2 million and 4.9 million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2016 and 2015, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 supersedes the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. The Company has not determined the impact of adopting ASU No. 2014-09 on our consolidated financial statements and currently plan to complete our evaluation by late 2017.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40) which requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity's ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management's plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management's plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the annual reporting period beginning after December 31, 2016. Early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.

In April 2015, the FASB issued ASU No. 2015-05, Intangibles, Goodwill and Other Internal-Use Software which includes guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The guidance is effective for reporting periods beginning after December 15, 2015, and can be adopted on either a prospective or retrospective basis. The Company adopted this guidance for the year ended December 31, 2016, on a prospective basis. The adoption of this new guidance did not have a material impact on the Company's financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Income Taxes, or ASU No. 2015-17. To simplify the presentation of deferred income taxes, the amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted. The amendments in this Update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We are currently evaluating the impact of adopting ASU No. 2015-17 on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation, or ASU No. 2016-09. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements.

Note 3 - Fair Value Measurements

The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable, approximate their fair values due to their short-term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of March 31, 2016
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,434,907	$	-	$	-	$	6,434,907
Total investment in money market funds	$	6,434,907	$	-	$	-	$	6,434,907

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304
Non-current portion of derivative instruments related to stock purchase warrants		-		-		-		-
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304

	As of December 31, 2015
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,430,561	$	-	$	-	$	6,430,561
Total investment in money market funds	$	6,430,561	$	-	$	-	$	6,430,561

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	16,411	$	16,411
Non-current portion of derivative instruments related to stock purchase warrants		-		-		491,791		491,791
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	508,202	$	508,202

(1)

Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

As of March 31, 2016, the Company did not have any transfers between Level 1 and Level 2 assets.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2016 and 2015:

	Balance as of		Unrealized			Balance as of
	December 31,		(Gains)			March 31,
Description	2015		2016			2016
Derivative liabilities related to stock purchase warrants	$	508,202	$	(39,898	)	$	468,304

	Balance as of		Unrealized			Balance as of
	December 31,		(Gains)			March 31,
Description	2014		2015			2015
Derivative liabilities related to stock purchase warrants	$	807,679	$	(338,245	)	$	469,434

At March 31, 2016 and 2015, derivative liabilities are comprised of warrants to purchase 1,275,419 and 1,775,419 shares of common stock, respectively. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in our unaudited condensed consolidated statements of operations.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. (See Note 2- Summary of Significant Accounting Policies). As of March 31, 2016, the Company had no other assets or liabilities that were measured at fair value on a non-recurring basis.

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively the development and marketing rights for SIGA’s drug candidate, Tecovirimat, also known as ST-246^®, pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with us.

In September 2014, SIGA filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”). SIGA’s petition for bankruptcy initiated a process whereby its assets were protected from creditors, including PharmAthene.

In January 2015, after years of litigation, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company’s lost profits for Tecovirimat, plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest.

On December 23, 2015, the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision as a result of which, with additional post-judgment interest, if calculated based on the original decision, would provide for an estimated total award of approximately $205 million.

On April 8, 2016, the Bankruptcy Court entered an order confirming SIGA’s Plan effective April 12, 2016 which provides for among other things, the process by which SIGA may emerge from bankruptcy, which includes the process by which our Judgment may be satisfied. The Plan provides generally that we will receive, in full settlement and satisfaction of our claim, no later than 120 days plus another potential 90 days after March 23, 2016 (generally considered to be no later than October 19, 2016), one of the following, determined in SIGA’s sole discretion:

(i)

payment in full in cash of the unpaid balance of our claim plus interest;

(ii)

delivery to us of 100% of SIGA’s common stock; or

(iii)

such other treatment as may be mutually agreed upon in writing by SIGA and PharmAthene and approved by the Bankruptcy Court.

If SIGA does not make its choice or satisfy the judgment in the manner in which it has chosen by October 19, 2016, we will receive 100% of SIGA by October 24, 2016.

From and after the Effective date (April 12, 2016), SIGA will compute interest on the outstanding balance of the judgment and pay us in arrears monthly. The interest will be computed at a rate of 8.75%. If SIGA decides to extend the 120 day period by an additional 90 days, the interest will be computed at the Delaware judgment interest rate which is currently 6%.

Under the Plan, we received an initial payment of $5 million from SIGA during April 2016 and during May 2016, received a first monthly payment calculated by SIGA as interest of approximately $0.9 million for the period April 12, 2016 through April 30, 2016. SIGA is required to pay us $20 million if it decides to extend the 120 day period by an additional 90 days. The payments are creditable against the final judgment and are not refundable.

The description of the Plan provided above is a brief summary of the Plan, which includes numerous other conditions and substantive provisions relating to the operation of the business of SIGA. Copies of the Plan are available from the Bankruptcy Court. For a description of risks related to our ability to recognize value relating to this litigation, see the “Risk Factors” section of our annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on March 11, 2016.

There can be no assurances if and when the Company will receive any additional payments from SIGA as a result of the Judgment. SIGA has indicated in filings with the Bankruptcy Court that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future. Our ability to collect the Judgment depends upon a number of factors, including SIGA’s financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA’s filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. The Company has not recognized any potential proceeds from these actions in the financial statements to date.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (“DCAA”) and other government agencies such as the Biomedical Advanced Research and Development Authority ("BARDA"). Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies. We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. As a result of the audit, we were able to record incremental revenue of $5.8 million in the first quarter of 2015 and payment in the second quarter of 2015.

BARDA has audited our 2014 costs related to the partial termination for convenience of the SparVax^® contract and forwarded the results to the pertinent U.S. Government Contracting Officer. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds.

Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company’s financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company’s financial condition and/or results of operations.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at March 31, 2016, which is not probable of payment, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $0.2 million for each month until the failure, if it occurs, is cured.

Leases

We lease our office in Maryland under a 10 year operating lease, which commenced on May 1, 2007. Remaining annual minimum payments are as follows:

Year	Lease Payments⁽¹⁾

2016	$	640,362
2017		356,911
	$	997,273

(1)

Minimum payments have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases.

On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space at an amount less than the Company’s leased amount.

The present value of the Company’s remaining net lease liability for the subleased office space (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses as follows:

Description	Present Value at March 31, 2016
Accrued restructuring expenses - current	$	255,551
Accrued restructuring expenses - long term	$	43,809

License Agreements

On July 6, 2015, we signed a license agreement with ImmunoVaccine Technologies (“IMV”) for the exclusive use of the DepoVax^TM vaccine platform (“DPX”), to develop an anthrax vaccine utilizing PharmAthene’s rPA. PharmAthene will reimburse up to $210,000 to IMV for their efforts in developing this vaccine and, in addition, PharmAthene will pay to IMV an annual payment of $200,000, additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets, and royalties on sales related to the use of DPX.

Note 5 - Stockholders’ Equity

Stockholder Rights Plan

On November 25, 2015, the Company’s Board of Directors adopted a stockholder rights plan (“Rights Plan”) in an effort to preserve the value of its net operating loss carryforwards (“NOLs”) under Section 382 of the Internal Revenue Code (the “Code”). The description and terms of the rights are set forth in a Section 382 Rights Agreement, dated as of November 25, 2015 (the “Section 382 Rights Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, as Rights Agent.

In connection with the adoption of the Rights Plan, on November 25, 2015 (the “Rights Dividend Declaration Date”), the Board declared a non-taxable dividend distribution of one share purchase right (“Right”) for each outstanding share of common stock to the Company's stockholders of record as of the close of business on December 9, 2015. The Section 382 Rights Plan is intended to act as a deterrent to any person (an “Acquiring Person”) acquiring (together with all affiliates and associates of such person) beneficial ownership of 4.99% or more of the Company’s outstanding common stock within the meaning of Section 382 of the Code, without the approval of the Board of Directors. Stockholders who beneficially owned 4.99% or more of the Company’s outstanding common stock as of the Rights Dividend Declaration Date are not be deemed to be an Acquiring Person, but such person will be deemed an Acquiring Person if such person (together with all affiliates and associates of such person) becomes the beneficial owner of securities representing a percentage of the Company’s common stock that exceeds by 0.5% or more the lowest percentage of beneficial ownership of the Company’s common stock that such person had at any time since the Rights Dividend Declaration Date. In its discretion, the Board may exempt certain persons whose acquisition of securities is determined by the Board not to jeopardize the availability to the Company's NOLs or other tax benefits and may also exempt certain transactions.

Long-Term Incentive Plan

In 2007, the Company’s stockholders approved the 2007 Long-Term Incentive Compensation Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

In 2008, our stockholders approved amendments to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January 1, 2015, or thereafter.

During the three months ended March 31, 2016, 16,900 stock options were exercised, 186,957 stock options were forfeited or expired, and 46,250 restricted stock awards were released. At March 31, 2016, there are approximately 10.3 million shares approved for issuance under the 2007 Plan, of which approximately 3.6 million shares are available for grant. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.

Warrants

At March 31, 2016 and 2015 there were warrants outstanding to purchase 1,422,781 and 1,922,781 shares of our common stock, respectively. The warrants outstanding as of March 31, 2016, all of which are exercisable, were as follows:

Number of Common Shares Underlying Warrants As of March 31, 2016			Issue Date	Exercise Price		Expiration Date
	100,778	⁽¹⁾	March 2007	$	3.97	March 2017
	903,996	⁽²⁾	July 2010	$	1.63	January 2017
	371,423	⁽²⁾	June 2011	$	3.50	June 2016
	46,584	⁽¹⁾	March 2012	$	1.61	March 2022
	1,422,781

(1)

These warrants to purchase common stock are classified as equity.

(2)

These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (See Note 3 – Fair Value Measurements) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

Note 6 – Financing Transactions

Controlled Equity Offering

On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent shares of our common stock having an aggregate offering price of up to $15.0 million.

On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent shares of our common stock having an aggregate offering price of up to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014 and will expire on May 30, 2017, three years from its effective date. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.

Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.

As of March 31, 2016, shares having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement, as amended. During the three months ended March 31, 2016, we did not sell any shares of our common stock under this arrangement. We have no current plans to sell any shares under the controlled equity agreement.

Note 7 – Subsequent Events

On April 8, 2016, the U.S. Bankruptcy Court for the Southern District of New York approved the Plan that lays out the terms and conditions under which SIGA will exit from bankruptcy, effective April 12, 2016. The Plan was negotiated between SIGA and the Statutory Creditor's Committee of which PharmAthene is a member. We received a $5 million initial payment from SIGA during April 2016 and during May 2016, received approximately $0.9 million, calculated by SIGA as interest on the judgment for the period April 12, 2016 through April 30, 2016. The payments are creditable against final satisfaction of our claim of approximately $208 million as of March 31, 2016 plus additional interest and are not refundable.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult to predict and may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risks associated with the following:

•

the risk that we will not be able to collect the full amount awarded to us by the Delaware Court of Chancery in January 2015 in connection with our claim under the lawsuit commenced in December 2006 against SIGA Technology, Inc., or SIGA,

•

subsequent proceedings in the Bankruptcy Court,

•

the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of our product candidates,

•

funding delays, reductions in or elimination of U.S. Government funding and/or non-renewal of expiring funding under our September 2014 contract with the National Institutes of Allergy and Infectious Diseases, or NIAID,

•

our ability to satisfy certain technical milestones under our September 2014 contract with NIAID that would entitle us to receive additional funding over the period of the agreement,

•

the preservation of our net operating loss carryforwards, or NOLs,

•

delays caused by third parties challenging government contracts awarded to us,

•

unforeseen safety and efficacy issues,

•

accomplishing any future strategic partnerships or business combinations,

•

our ability to continue to satisfy the listing requirements of the NYSE MKT,

as well as risks detailed under the caption “Risk Factors” in this quarterly report on Form 10-Q and in our other reports filed with the U.S. Securities and Exchange Commission, or the SEC, from time to time hereafter.

Forward-looking statements describe management’s current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential” or “plan” or the negative of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to, statements relating to:

•

outcomes under SIGA’s bankruptcy proceedings,

•

anticipated results of pending litigation,

•

potential payments under government contracts or grants,

•

potential future government contracts or grant awards,

•

potential regulatory approvals,

•

future product advancements, and

•

anticipated financial or operational results.

Forward-looking statements are based on assumptions that may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this Quarterly Report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three months ended March 31, 2016 and 2015, as well as our financial positions at March 31, 2016 and December 31, 2015, contained elsewhere in this Quarterly Report on Form 10-Q. The following discussion should also be read in conjunction with the Annual Report on Form 10-K for the year ended December 31, 2015, filed on March 11, 2016, including the consolidated financial statements contained therein.

Overview

Since 2006, we have been engaged in legal proceedings with SIGA. On December 23, 2015, the Delaware Supreme Court affirmed the Delaware Court of Chancery's judgment against SIGA which provides an estimated total award of approximately $205 million plus interest. On April 8, 2016, the Bankruptcy Court entered an order confirming SIGA’s Plan effective April 12, 2016 which provides for SIGA to emerge from bankruptcy and provides various alternatives for the final resolution of our litigation claim against SIGA during 2016. The Plan provides generally that we will receive, in full settlement and satisfaction of our claim, no later than 120 days plus another potential 90 days after March 23, 2016 (generally considered to be no later than October 19, 2016). Under the Plan, we received an initial payment of $5 million from SIGA during April 2016 and during May 2016, received approximately $0.9 million, calculated by SIGA as interest on the judgment for the period April 12, 2016 through April 30, 2016.

During the first half of 2015 we narrowed the scope of our product development programs, reduced our employee headcount and executed other cost reductions. These actions have allowed us to have sufficient cash to recognize the benefit of the SIGA award and advance our Anthrax vaccine programs without the need to raise additional capital. During the second half of 2015 we focused our efforts on creating alternatives for settling the SIGA litigation claim and developing business plans around possible outcomes.

During 2016, we will continue to develop our plans to create shareholder value from the alternative SIGA litigation outcomes, which are discussed further in the section entitled “Item 1. - Legal Proceedings”, and will commence execution of those plans.

Post-SIGA Payment Plans

In the event that SIGA pays us cash in full and barring any unexpected material events, we currently expect that we will distribute at least 90% of the after tax net cash proceeds to our shareholders. The timing and form of distribution will depend upon our analysis of the Company’s current situation, applicable corporate statutes relating to distributions and the economic consequences to our shareholders. After distribution of these cash proceeds, we intend to seek an M&A transaction to maximize the value of the Company’s remaining assets and anthrax vaccine programs.

We will develop a transition plan and strategy for operating SIGA as a separate business in the event SIGA chooses to pay our claim by turning over 100% of its common stock to us.

Net Operating Loss

We anticipate that eventual receipt of an award from SIGA could generate substantial taxable income to us, a portion of which can potentially be offset by our tax NOL carryforwards. At December 31, 2015, we had available $156 million in accumulated losses available to offset income, subject to limitations imposed by the U.S. Internal Revenue Code of 1986 (the “Code”). On November 25, 2015, we adopted a Shareholders Rights Plan to help ensure that the NOLs remain available to help maximize the value for our shareholders of any amount received from the SIGA litigation.

We are currently evaluating the impact on our U.S. NOLs from the wind down of our UK operations. The estimated range for the increase in the NOL from the wind down of our UK operations is from $9 million to $22 million.

Under Section 382 of the U.S. Internal Revenue Code, our U.S. federal NOLs may be limited due to certain underlying ownership changes of our common stock. Our most recent analysis under Section 382 determined that there has been no impact on our ability to utilize our U.S. federal NOLs as the result of any prior ownership change. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership that could result in further limitations being placed on our ability to utilize our U.S. federal NOLs.

Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

A summary of our critical accounting policies, including those that require the use of significant estimates and judgment, follows. A more comprehensive description of all of our significant accounting policies is contained in Note 2 to our Consolidated Financial Statements.

There were no significant changes in critical accounting policies from those at December 31, 2015.

Results of Operations

Revenue

Our revenue was derived primarily from contracts with the U.S. Government for the development of anthrax vaccine programs. Our revenue in the three months ended March 31, 2016 changed from the comparable period of 2015 primarily due to the following:

Under our existing contract with NIAID for the development of a next generation lyophilized anthrax vaccine based on the Company’s proprietary technology platform which contributes the rPA bulk drug substance that is used in the liquid SparVax^® formulation, we recognized $1.0 million during each of the three months ended March 31, 2016 and 2015. Revenue recognized to date under this contract is $6.1 million.

Under our contract for the development of SparVax^®, we recognized approximately $6.1 million in revenue for the three months ended March 31, 2015 which was primarily attributable to the receipt of a one-time payment as a result of an audit completed by BARDA and contract wind-up activity. We anticipate that revenue for this program will be mostly for rate variances and will be significantly less in 2016 than in 2015.

Research and Development Expenses

Our research and development expenses were $1.0 million and $1.6 million for the three months ended March 31, 2016 and March 31, 2015, respectively. These expenses resulted from research and development activities in all periods related primarily to our anthrax vaccine programs. Direct expenses included salaries and other costs of personnel, raw materials and supplies, and an allocation of indirect expenses. We also incurred third-party costs, such as contract research, consulting, and clinical development costs for individual projects.

For the three months ended March 31, 2016, research and development expenses decreased $0.6 million from the same period in the prior year. In accordance with the Realignment Plan, or Realignment Plan, approved by our Board on March 9, 2015 (with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from the SIGA litigation and our existing biodefense assets, and which plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time expected to extend beyond our collection of the amount awarded to us by the Delaware Chancery Court's affirmed judgment), labor and related indirect costs decreased period over period. In addition, costs were incurred in 2015 to further the NIAID (lyophilized) program.

General and Administrative Expenses

General and administrative functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal, and compliance. For each function, we may incur expenses such as salaries, supplies and third-party consulting and other external costs and non-cash expenditures such as expense related to stock option and restricted share awards. An allocation of indirect costs such as facilities, utilities, and other administrative overhead is also included in general and administrative expenses.

Expenses associated with general and administrative functions were $1.2 million for the three months ended March 31, 2016 and $2.2 million for the three months ended March 31, 2015. The $1.0 million decrease from the same period in the prior year was primarily due to a reduction in employee costs resulting from our implementation of the Realignment Plan and a reduction in legal expenses.

Other Income (Expense)

Other income (expense) primarily consists of changes in the fair value of our derivative financial instruments and interest expense on our debt and other financial obligations. For the three months ended March 31, 2016 and 2015, other income was $0.04 million and $0.3 million, respectively. This was primarily the result of unrealized gains on the change in the fair value of the derivative instruments of $0.04 million and $0.3 million for the three months ended March 31, 2016 and 2015, respectively.

The $5 million initial payment the Company received from SIGA during April 2016 and first monthly payment of approximately $0.9 million, calculated by SIGA as interest for the period April 12, 2016 through April 30, 2016, and received from SIGA during May 2016, will be recognized as other income during the second quarter of 2016.

Income Taxes

The provision for income taxes was $0.02 million for each of the three months ended March 31, 2016 and 2015. Our provision for income taxes results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.

Liquidity and Capital Resources

Overview

Our primary source of cash during the three months ended March 31, 2016 was $1.0 million in proceeds paid under our contract with NIAID. Our primary sources of cash during the comparable period in 2015 were $0.5 million in proceeds paid under our contract with NIAID and $0.4 million in proceeds paid under our contract with BARDA. Our cash and cash equivalents were $14.2 million and $15.6 million at March 31, 2016 and December 31, 2015, respectively. We believe, based on the operating cash requirements and capital expenditures expected for 2016, the Company's cash on hand at March 31, 2016 plus the $5 million initial payment received from SIGA during April 2016 and approximately $0.9 million first monthly payment, calculated by SIGA as interest for the period April 12, 2016 through April 30, 2016, and received from SIGA during May 2016, is adequate to fund operations through at least the next twelve months.

As noted above, in 2014, BARDA audited indirect costs or rates charged by us on the SparVax^® contract for the years 2008 through 2013. We had billed and recognized revenue using the provisional rates as defined in the contract. As a result of the audit, we were able to record incremental revenue of $5.8 million in the first quarter of 2015 and payment in the second quarter of 2015, representing the difference between actual rates (i.e., actual cost to us) and the provisional rates used to calculate previously billed and recognized revenue. BARDA has audited our 2014 costs related to the partial termination for convenience of the SparVax® contract. While we do not currently believe the results of this audit will have an adverse effect on us, we cannot provide assurances that it will not have such an effect; furthermore, in 2014, we believe that our actual rates exceeded our provisional rates.

Our sole sources of revenue consist of (1) revenues related to the audit of the BARDA contract and (2) revenues under our September 2014 contract with NIAID for the development of a next generation lyophilized anthrax vaccine based on our proprietary technology platform which contributes the rPA bulk drug substance that is used in the liquid SparVax^® formulation.

The NIAID agreement is incrementally funded. Over the base period of the agreement, we were awarded initial funding of approximately $5.2 million, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestones. NIAID exercised the first and second options under this agreement in 2015. The exercised options provide additional funding of approximately $4.9 million and an extension of the period of performance through April 30, 2017. Through March 31, 2016, the Company has recognized $6.1 million of revenue under the contract. The contract has a total value of up to approximately $28.1 million, if all technical milestones are met and all eight contract options are exercised by NIAID. NIAID may exercise options at its discretion and if all options are exercised, the contract would last approximately five years.

We have incurred significant losses since we commenced operations. As of March 31, 2016, we had accumulated losses of $225.0 million since our inception. While we have undertaken efforts to reduce expenses, if we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.

Historically, we have not generated positive cash flows from operations. To bridge the gap between payments made to us under our U.S. Government contracts and grants and our operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity and equity-linked securities and proceeds from loans and other borrowings. On March 25, 2013, we entered into a controlled equity offering arrangement pursuant to which we could offer and sell, from time to time, through a sales agent, shares of our common stock having an aggregate offering price of up to $15.0 million, which we later amended on May 23, 2014 to increase the offering amount by $15.0 million. During the three months ended March 31, 2016, we did not sell any shares of our common stock under this arrangement. Aggregate gross proceeds of up to $3.0 million remain available under this arrangement. We have no current plans to sell any shares under the controlled equity agreement.

We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to maintain our operations, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets. In addition, executive officers who have served the Company for many years have been terminated, and, with the exception of Eric Richman’s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until we have received SIGA’s payment. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to enforce payment of or collect the damages award from SIGA, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.

In addition, we may voluntarily elect to raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.

Cash Flows

The following table provides information regarding our cash flows for the three months ended March 31, 2016 and 2015:

	Three months ended March 31,
	2016			2015
Net cash provided by (used in):
Operating activities	$	(1,355,142	)	$	(2,713,361	)
Investing activities		(150	)		(27,752	)
Financing activities		22,352			(165,667	)
Effects of exchange rates on cash		(1,252	)		(11,615	)
Total decrease in cash and cash equivalents	$	(1,334,192	)	$	(2,918,395	)

Operating Activities

Net cash used by operating activities was $1.4 million for the three months ended March 31, 2016 compared to $2.7 million which was provided by operating activities for the three months ended March 31, 2015.

Net cash used by operating activities during the three months ended March 31, 2016 reflects our net loss of $1.2 million, adjusted for non-cash share-based compensation expense of $0.2 million, the decrease in the fair value of our derivative instruments of $0.04 million, and other non-cash expenses of $0.06 million. A decrease in billed receivables of approximately $0.3 million was offset by a $0.3 million increase in both unbilled receivables and prepaid expenses and other current assets. Accounts payable and accrued expenses and other liabilities increased by a combined $0.1 million and accrued restructuring expenses decreased by $0.2 million.

Net cash used by operating activities during the three months ended March 31, 2015 reflects our net income of $1.5 million offset by a reduction in non-cash expenses of $0.1 million. Receivables and prepaid expenses increased by $6.4 million mainly due to the $5.8 million invoice to BARDA. Accounts payable and accrued expenses and other liabilities increased by $0.4 million and accrued restructuring expenses were $1.9 million.

Investing Activities

There were no significant investing activities during the three months ended March 31, 2016 and March 31, 2015.

Financing Activities

Net cash provided by financing activities was $0.02 million for the three months ended March 31, 2016, as compared to $0.2 million used by financing activities for the three months ended March 31, 2015.

Net cash provided by financing activities during the three months ended March 31, 2016 was primarily due to net proceeds received of $0.02 million from the issuance of common stock due to stock options exercised.

Net cash used by financing activities during the three months ended March 31, 2015 was primarily due to repayment of debt. This was partially offset by net proceeds received of $0.08 million from the issuance of common stock due to stock options exercised.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

The following are contractual commitments at March 31, 2016:

Contractual Obligations⁽¹⁾	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 Years
Operating facility leases⁽²⁾	$	997,274	$	854,509	$	142,765	$	-	$	-
Research and development agreements		1,079,031		1,079,031		-		-		-
Total contractual obligations	$	2,076,305	$	1,933,540	$	142,765	$	-	$	-

(1)

This table does not include any royalty payments relating to future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology, as the timing and likelihood of such payments are not known. The table also excludes any obligations related to registration rights agreements, as a result of a maintenance failure (as defined in such agreements), as the likelihood of any such payment is not probable. See additional discussion in Note 4 – Commitments and Contingencies in the unaudited condensed consolidated financial statements which are included in Part 1 of this Form 10-Q.

(2)

Lease obligations have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

The Company’s current operations in foreign countries are minimal. We had maintained only nominal operations in the United Kingdom, but those operations were substantially liquidated in the second quarter of 2015. A 10% change in exchange rates (against the U.S. dollar) would not have a material impact on earnings, fair values or cash flow.

Because of the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market interest rates would have a significant impact on their realized value.

The change in fair value of our derivative instruments is calculated utilizing the Black-Scholes option pricing model; therefore, a 10% increase/decrease in the closing price of the Company’s common stock at March 31, 2016, would result in a change in fair value of derivative instruments and our earnings of approximately $0.1 million.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2016. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended March 31, 2016, and has concluded that there was no change that occurred during the quarterly period ended March 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Except as noted below, we are not a party to any material legal proceedings.

In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively the development and marketing rights for SIGA’s drug candidate, Tecovirimat, pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with us.

In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us, upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery’s finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court’s opinion.

On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company’s lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company’s reasonable attorneys’ and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.

On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"). SIGA’s petition for bankruptcy initiated a process whereby its assets were protected from creditors, including us.

On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015.

On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the Total Judgment, comprised of (1) expectation damages of $113.1 million, for the value of the Company’s lost profits for Tecovirimat, also known as ST-246^® (formerly referred to as “Arestvyr™” and referred to by SIGA in its recent SEC filings as “Tecovirimat”), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company’s reasonable attorneys’ and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest.

(i)

payment in full in cash of the unpaid balance of our claim plus interest;

(ii)

delivery to us of 100% of SIGA’s common stock; or

(iii)

such other treatment as may be mutually agreed upon in writing by SIGA and PharmAthene and approved by the Bankruptcy Court.

If SIGA does not make its choice or satisfy the judgment in the manner in which it has chosen by October 19, 2016, we will receive 100% of SIGA by October 24, 2016.

From and after the Effective date (April 12, 2016), SIGA will compute interest on the outstanding balance and pay us in arrears monthly. The interest will be computed at a rate of 8.75%. If SIGA decides to extend the 120 day period by an additional 90 days, the interest will be computed at the Delaware judgment interest rate which is currently 6%.

Under the Plan, we received an initial payment of $5 million from SIGA during April 2016 and during May 2016, received approximately $0.9 million, calculated by SIGA as interest for the period April 12, 2016 through April 30, 2016. SIGA is required to pay us $20 million if it decides to extend the 120 day period by an additional 90 days. The payments are creditable against the final judgment and are not refundable.

Post-SIGA Payment Plans

We will develop a transition plan and strategy for operating SIGA as a separate business in the event SIGA chooses to pay our claim by turning over 100% of its common stock to us.

Item 1A. Risk Factors

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits.

No.		Description
31.1		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

31.2		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)

32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350

32.2		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350

(101)		The following condensed consolidated financial statements from the PharmAthene, Inc. Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2016, formatted in Extensive Business Reporting Language ("XBRL"): (i) Condensed Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015, (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2016 and 2015, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015, and (v) Notes to consolidated financial statements.

101.INS		Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMATHENE, INC.

Dated: May 9, 2016	By:	/s/ John M. Gill
		Name: John M. Gill
		Title: President and Chief Executive Officer

Dated: May 9, 2016	By:	/s/ Philip MacNeill
		Name: Philip MacNeill
		Title: Chief Financial Officer, Treasurer and Secretary

EX-31.1 2 v437892_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, John M. Gill, certify that:

1.	I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended March 31, 2016;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 9, 2016	/s/ John M. Gill
	Name: John M. Gill
	Title: President and Chief Executive Officer

EX-31.2 3 v437892_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Philip MacNeill, certify that:

1.	I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended March 31, 2016;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 9, 2016	/s/ Philip MacNeill
	Name: Philip MacNeill
	Title: Chief Financial Officer, Treasurer and Secretary

EX-32.1 4 v437892_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, John M. Gill, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ John M. Gill
Name: John M. Gill
Title: President and Chief Executive Officer
May 9, 2016

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-32.2 5 v437892_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended March 31, 2016, as filed with the Securities and Exchange Commission (the “Report”), I, Philip MacNeill, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Philip MacNeill
Name: Philip MacNeill
Title: Chief Financial Officer, Treasurer and Secretary
May 9, 2016

EX-101.INS 6 pip-20160331.xml XBRL INSTANCE DOCUMENT 0001326190 2015-01-01 2015-01-31 0001326190 2015-01-01 2015-03-31 0001326190 2016-01-01 2016-03-31 0001326190 2015-01-31 0001326190 2015-03-31 0001326190 2016-03-31 0001326190 2016-05-01 0001326190 2015-07-06 0001326190 2014-09-09 0001326190 2015-11-25 0001326190 2015-12-01 2015-12-23 0001326190 2015-12-31 0001326190 2014-12-31 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001326190 us-gaap:RestructuringChargesMember 2016-01-01 2016-03-31 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-03-31 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0001326190 us-gaap:RestructuringChargesMember 2015-01-01 2015-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2016-01-01 2016-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2016-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-01-01 2015-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2014-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-03-31 0001326190 pip:GroupFourMember 2016-01-01 2016-03-31 0001326190 pip:GroupThreeMember 2016-01-01 2016-03-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember us-gaap:MaximumMember 2008-12-31 0001326190 pip:DerivativeLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2016-03-31 0001326190 pip:DerivativeLiabilitiesMember us-gaap:FairValueInputsLevel3Member 2015-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeOneMember us-gaap:WarrantMember 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeTwoMember pip:DerivativeInstrumentWarrantsMember 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeThreeMember pip:DerivativeInstrumentWarrantsMember 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeFourMember us-gaap:WarrantMember 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeOneMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeTwoMember pip:DerivativeInstrumentWarrantsMember 2016-01-01 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeThreeMember pip:DerivativeInstrumentWarrantsMember 2016-01-01 2016-03-31 0001326190 pip:ShareBasedCompensationWarrantsPriceRangeFourMember us-gaap:WarrantMember 2016-01-01 2016-03-31 0001326190 pip:EquityOfferingMember 2013-03-25 0001326190 pip:AmendmentToControlledEquityOfferingMember 2014-05-23 0001326190 pip:EquityOfferingMember 2016-03-31 0001326190 pip:SigaTechnologiesIncMember us-gaap:SubsequentEventMember 2016-04-01 2016-05-31 0001326190 pip:SigaTechnologiesIncMember us-gaap:SubsequentEventMember 2016-04-01 2016-04-30 0001326190 us-gaap:EmployeeSeveranceMember 2015-12-31 0001326190 pip:SubleaseExpensesMember 2015-12-31 0001326190 us-gaap:EmployeeSeveranceMember 2016-01-01 2016-03-31 0001326190 pip:SubleaseExpensesMember 2016-01-01 2016-03-31 0001326190 us-gaap:EmployeeSeveranceMember 2016-03-31 0001326190 pip:SubleaseExpensesMember 2016-03-31 0001326190 pip:SigaTechnologiesIncMember us-gaap:SubsequentEventMember 2016-04-01 2016-04-13 0001326190 pip:SigaTechnologiesIncMember us-gaap:SubsequentEventMember 2016-10-24 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2016-03-31 0001326190 pip:SigaTechnologiesIncMember 2016-01-01 2016-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 10-Q false 2016-03-31 2016 Q1 PHARMATHENE, INC 0001326190 --12-31 Accelerated Filer PIP 65591840

14235621

15569813

170323

511994

1266820

963345

463873

181714

16136637

17226866

196143

233694

53384

2348453

18734617

19862397

166357

521122

1749899 1248708

255551

381950

11250

468304

16411

2640111

2179441

43809

108641

424213

433407

491791

3108133

3213280

6444

6438

240570971

240366704

-224950931

-223724025

15626484

16649117

18734617

19862397

1005694

7068746

1029131

1613627

1193298

2196120

2060809

37701

37106

2260130

5907662

-1254436

1161084

1050

25325

39898

338245

4119

9196

42967

322116

-1211469

1483200

15437

19805

-1226906

1463395

1746

-1226906

1465141

181921

199627

15437

19805

5485

10933

7600

303475

296828

282160

253779

-354765

146740

-196716

1938631

466563

230186

-1355142

-2713361

150

35352

7600

-150

-27752

-249999

22352

-165667

-1252

-11615

-1334192

-2918395

18643351

15724956

14849

1400000

181926

199627

29293

152633

60735

192633

-53741

75000 129000 53741

20000

6434907

468304

6430561

16411

491791

508202

39898

468304

338245

807679

469434

205000000

0.010 200000 0.010 200000 0.0499

3500000

4600000

1422781

1922781

0.0001

100000000

64444725

64382086

-0.02

0.02

-0.02

0.02

64404396

63633290

64404396

63979859

-341671

5863332

23237

84332

-885

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note 1 - Business and Liquidity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We are a biodefense company engaged in developing two next generation anthrax vaccines. The next generation vaccines are intended to have more rapid time to protection, fewer doses for protection and less stringent requirements for temperature controlled storage and handling than the currently used vaccine.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Since 2006, we have been engaged in legal proceedings with SIGA Technologies, Inc. (“SIGA”). On December 23, 2015, the Delaware Supreme Court affirmed the Delaware Court of Chancery's judgment against SIGA which provides an estimated total award of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">208</font> million as of March 31, 2016 plus additional interest. On April 8, 2016, the Bankruptcy Court entered an order confirming SIGA’s third amended Reorganization Plan (the “Plan”) effective April 12, 2016 which provides for SIGA to emerge from bankruptcy and provides various alternatives for the final resolution of our litigation claim against SIGA during 2016. Under the Plan, we received an initial payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> million from SIGA during April 2016 and during May 2016, received approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.9</font> million, calculated by SIGA as interest on the judgment for the period of April 12, 2016 through April 30, 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the first half of 2015, we narrowed the scope of our product development programs, reduced our employee headcount and executed other cost reductions. These actions have allowed us to have sufficient cash to recognize the benefit of the SIGA award and advance our Anthrax vaccine programs without the need to raise additional capital. During the second half of 2015, we focused our efforts on creating alternatives for settling the SIGA litigation claim and developing business plans around possible outcomes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During 2016, we will continue to develop our plans to create shareholder value from the alternative SIGA litigation outcomes and will commence execution of those plans.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On September 9, 2014, we signed a contract with the National Institutes of Allergy and Infectious Diseases (“NIAID") for the development of a next generation lyophilized anthrax vaccine based on our proprietary technology platform which contributes the recombinant protective antigen (“rPA”) bulk drug substance that is used in the liquid SparVax<sup style="font-style:normal">®</sup> formulation. The contract is incrementally funded. Over the base period of the contract, we were awarded initial funding of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.2</font> million, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestones. NIAID exercised the first and second options under this agreement in September 2015 and December 2015, respectively. The exercised options provide additional funding of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.9</font> million and an extension of the period of performance through April 30, 2017. The contract has a total value of up to approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">28.1</font> million, if all technical milestones are met and all eight contract options are exercised by NIAID. If NIAID exercises all options, the contract would last approximately five years. If NIAID does not exercise any additional options, the contract would expire by its terms on April 30, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of March 31, 2016, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.2</font> million, our accounts receivable (billed and unbilled) balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million, and our current liabilities were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.6</font> million. We believe, based on the operating cash requirements and capital expenditures expected for 2016, the Company’s cash on hand at March 31, 2016 plus the $5 million initial payment received from SIGA during April 2016 and approximately $0.9 million, calculated by SIGA as interest, and received from SIGA during May 2016, is adequate to fund operations for at least the next twelve months.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

28100000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Note 2 - Summary of Significant Accounting Policies</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2015 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC. We currently operate in one business segment.</div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Foreign Currency Translation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The functional currency of our wholly owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders’ equity. Transaction gains or losses are included in the determination of net loss.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In June 2015, we substantially liquidated PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Cash and cash equivalents are stated at market value which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Significant Customers and Accounts Receivable</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our primary customer is NIAID. As of March 31, 2016 and December 31, 2015, the Company’s receivable balances (both billed and unbilled) were comprised solely of receivables from NIAID.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Goodwill</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"> </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2015 and determined that there was no impairment as of that date. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"> </font></i> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued Restructuring Expense</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued restructuring expense as of March 31, 2016 is as follows: <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Paid</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued severance expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued sublease expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>358,769</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total accrued restructuring expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>490,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</i></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3- <i>Fair Value Measurements</i> for further details.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"> </font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We generate our revenue from cost-plus-fee contracts and in the past, have generated revenue from fixed price contracts.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Milestones are considered substantive if all of the following conditions are met:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.35pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -16.5pt; MARGIN: 0in 0in 0pt 33pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.35pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">it relates solely to past performance, and</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -16.5pt; MARGIN: 0in 0in 0pt 33pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 9.35pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="12"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Upon notice of termination of a contract from the government, all related termination costs are expensed. If there is assurance that collection is reasonably assured, then revenue is taken as if the contract was a cost-plus-fee contract.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Collaborative Arrangements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Even though most of our products are being developed in conjunction with support by the U.S. Government, we are an active participant in that development, with exposure to significant risks and rewards of commercialization relating to the development of these pipeline products. In collaborations where we are deemed to be the principal participant of the collaboration, we recognize costs and revenues generated from third parties using the gross basis of accounting; otherwise, we use the net basis of accounting. Cost paid to us by other collaborative arrangement members are recognized pursuant to their terms.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> Research and development costs are expensed as incurred; up-front payments are deferred and expensed as performance occurs. Research and development costs include salaries, facilities expense, overhead expenses, material and supplies, preclinical expense, clinical trials and related clinical manufacturing expenses, share-based compensation expense, contract services and other outside services.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Share-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We expense the estimated fair value of share-based awards granted to employees, non-employee directors and consultants under our stock compensation plans.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model, which considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of stock options granted to consultants is determined at the grant date using the Black-Scholes option pricing model and remeasured at each quarterly reporting date over their requisite service period. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of restricted stock grants granted to employees and non-employee directors is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of restricted stock grants granted to consultants is determined based on the closing price of our common stock on the award date, is remeasured at each quarterly reporting date and is recognized as expense ratably over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Employee share-based compensation expense recognized in the three months ended March 31, 2016 and 2015 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font></font>%, based on historical forfeitures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three months ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">29,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">60,735</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">152,633</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">192,633</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Restructuring benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(53,741)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Total share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">181,926</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">199,627</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As a result of the restructuring and termination of employees, during the three months ended March 31, 2015, we recognized approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">129,000</font> of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,741</font> net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the three months ended March 31, 2016, we made no stock option or restricted stock grants. During the three months ended March 31, 2015, we granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000</font> options and made <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 117,500</font> shares of restricted stock grants to employees. At March 31, 2016, we had total unrecognized share-based compensation expense related to unvested awards of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.9</font> years.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of March 31, 2016, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Income tax expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.02</font> million during each of the three months ended March 31, 2016 and 2015, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our consolidated balance sheets.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basic and Diluted Net Loss Per Share</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Income (loss) per share:</font></i> <font style="FONT-SIZE: 10pt"> Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potentially dilutive common shares, consisting  primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses. A total of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6.2</font> million and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4.9</font> million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2016 and 2015, respectively, because their inclusion would be anti-dilutive.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"> </font></i> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 supersedes the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. The Company has not determined the impact of adopting ASU No. 2014-09 on our consolidated financial statements and currently plan to complete our evaluation by late 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40) which requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity's ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management's plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management's plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the annual reporting period beginning after December 31, 2016. Early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In April 2015, the FASB issued ASU No. 2015-05, Intangibles, Goodwill and Other Internal-Use Software which includes guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The guidance is effective for reporting periods beginning after December 15, 2015, and can be adopted on either a prospective or retrospective basis. The Company adopted this guidance for the year ended December 31, 2016, on a prospective basis. The adoption of this new guidance did not have a material impact on the Company's financial statements.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2015, the FASB issued ASU No. 2015-17, Income Taxes, or ASU No. 2015-17. To simplify the presentation of deferred income taxes, the amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted. The amendments in this Update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We are currently evaluating the impact of adopting ASU No. 2015-17 on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU No. 2016-09, Compensation  Stock Compensation, or ASU No. 2016-09. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.12 0.12

12000

117500

1000000

P1Y10M24D

6200000

4900000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Note 3 - Fair Value Measurements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable, approximate their fair values due to their short-term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 1  Quoted prices in active markets for identical assets or liabilities.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 1.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 2  Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 1.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">•</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Level 3  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> As of March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Investment in money market funds<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total investment in money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Non-current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Investment in money market funds<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total investment in money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">16,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">16,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Non-current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">491,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">491,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">508,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">508,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</font></div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As of March 31, 2016 the Company did not have any transfers between Level 1 and Level 2 assets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2016 and 2015:</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Gains)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="57%"> <div style="CLEAR:both;CLEAR: both">Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="57%"> <div style="CLEAR:both;CLEAR: both">Derivative liabilities related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">508,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(39,898)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Unrealized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">(Gains)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="61%"> <div style="CLEAR:both;CLEAR: both">Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="61%"> <div style="CLEAR:both;CLEAR: both">Derivative liabilities related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">807,679</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(338,245)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">469,434</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">At March 31, 2016 and 2015, derivative liabilities are comprised of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,275,419</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,775,419</font> shares of common stock, respectively. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in our unaudited condensed consolidated statements of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="99%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Quantitative Information about Level 3 Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="31%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Fair Value at March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%"> <div style="CLEAR:both;CLEAR: both"> Valuation  Technique</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%"> <div style="CLEAR:both;CLEAR: both">Unobservable Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> Black-Scholes option pricing model</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Anticipated volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a non-recurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. (See Note 2- <i>Summary of Significant</i> <i>Accounting Policies</i>). As of March 31, 2016, the Company had no other assets or liabilities that were measured at fair value on a non-recurring basis.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> As of March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Investment in money market funds<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total investment in money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,434,907</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Non-current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="55%" colspan="11"> <div style="CLEAR:both;CLEAR: both"> As of December 31, 2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 1</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 2</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Level 3</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Balance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Investment in money market funds<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total investment in money market funds</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">6,430,561</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">Liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">16,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">16,411</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Non-current portion of derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">491,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">491,791</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Total derivative instruments related to stock purchase warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">508,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">508,202</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="99%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Quantitative Information about Level 3 Fair Value Measurements</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="31%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> Fair Value at March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%"> <div style="CLEAR:both;CLEAR: both"> Valuation  Technique</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="33%"> <div style="CLEAR:both;CLEAR: both">Unobservable Inputs</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both">468,304</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> Black-Scholes option pricing model</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Expected term</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="30%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="33%"> <div style="CLEAR:both;CLEAR: both">Anticipated volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

468304

1275419

1775419

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Remaining annual minimum payments are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both; size: 8.5in 11.0in" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="MARGIN: 0px:auto; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Lease Payments<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">640,362</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">356,911</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">997,273</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="4%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="4%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="92%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Minimum payments have not been reduced by the minimum sublease rentals of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million due in the future under noncancellable subleases.</font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

640362

356911

997273

255551

43809

1 P10Y

200000

210000 200000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The warrants outstanding as of March 31, 2016, all of which are exercisable, were as follows:</font></div> <font style="FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="2"> <div>Number of Common Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="2"> <div>Underlying Warrants As of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="2"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="2"> <div>March 31, 2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Issue Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="2"> <div>Exercise Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%"> <div>Expiration Date</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%"> <div>100,778<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="24%"> <div>March 2007</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="22%"> <div>3.97</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="24%"> <div>March 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>903,996<sup style="font-style:normal">(2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>July 2010</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="22%"> <div>1.63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>January 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>371,423<sup style="font-style:normal">(2)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>June 2011</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="22%"> <div>3.50</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>June 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="23%"> <div>46,584<sup style="font-style:normal">(1)</sup></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>March 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="22%"> <div>1.61</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div>March 2022</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="23%"> <div>1,422,781</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="22%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="24%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="92%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">These warrants to purchase common stock are classified as equity.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="3%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt"> </font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="5%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(2)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 92%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="92%"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (See Note 3  <i>Fair Value Measurements</i>) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).</font></div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

3.97

1.63

3.50

1.61

2017-03-01 2017-01-01 2016-06-01 2022-03-01 2007-03-01 2010-07-01 2011-06-01 2012-03-01

100778

903996

371423

46584

15000000 15000000 0.030 3000000

5000000

2015-01-28

20000

5200000 4900000 900000

131822

490591

358769

131822

59409

299360

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <i>Collaborative Arrangements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Even though most of our products are being developed in conjunction with support by the U.S. Government, we are an active participant in that development, with exposure to significant risks and rewards of commercialization relating to the development of these pipeline products. In collaborations where we are deemed to be the principal participant of the collaboration, we recognize costs and revenues generated from third parties using the gross basis of accounting; otherwise, we use the net basis of accounting. Cost paid to us by other collaborative arrangement members are recognized pursuant to their terms.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> <i>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> Research and development costs are expensed as incurred; up-front payments are deferred and expensed as performance occurs. Research and development costs include salaries, facilities expense, overhead expenses, material and supplies, preclinical expense, clinical trials and related clinical manufacturing expenses, share-based compensation expense, contract services and other outside services.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

194600000

113100000

81500000

The interest will be computed at a rate of 8.75%. If SIGA decides to extend the 120 day period by an additional 90 days, the interest will be computed at the Delaware judgment interest rate which is currently 6%. 1

20000000

5800000

46250

186957

16900

10300000

3600000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Accrued Restructuring Expense</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accrued restructuring expense as of March 31, 2016 is as follows: <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Paid</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued severance expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued sublease expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>358,769</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total accrued restructuring expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>490,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <i>Recent Accounting Pronouncements</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU No. 2014-09”). ASU No. 2014-09 supersedes the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. The Company has not determined the impact of adopting ASU No. 2014-09 on our consolidated financial statements and currently plan to complete our evaluation by late 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements, Going Concern (Subtopic 205-40) which requires management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity's ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management's plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management's plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the annual reporting period beginning after December 31, 2016. Early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: left; MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt"> In April 2015, the FASB issued ASU No. 2015-05, Intangibles, Goodwill and Other Internal-Use Software which includes guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The guidance is effective for reporting periods beginning after December 15, 2015, and can be adopted on either a prospective or retrospective basis. The Company adopted this guidance for the year ended December 31, 2016, on a prospective basis. The adoption of this new guidance did not have a material impact on the Company's financial statements.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In November 2015, the FASB issued ASU No. 2015-17, Income Taxes, or ASU No. 2015-17. To simplify the presentation of deferred income taxes, the amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted. The amendments in this Update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We are currently evaluating the impact of adopting ASU No. 2015-17 on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this Update supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this Update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU No. 2016-02 on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU No. 2016-09, Compensation  Stock Compensation, or ASU No. 2016-09. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in this Update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. We are currently evaluating the impact of adopting ASU No. 2016-09 on our consolidated financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Accrued restructuring expense as of March 31, 2016 is as follows: <i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Balance as of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Paid</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Amortized</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>Description</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="51%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued severance expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Accrued sublease expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>358,769</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Total accrued restructuring expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>490,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>131,822</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>59,409</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>299,360</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

208000000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 16.5pt; MARGIN: 0in 0in 0pt"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Share-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We expense the estimated fair value of share-based awards granted to employees, non-employee directors and consultants under our stock compensation plans.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model, which considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of stock options granted to consultants is determined at the grant date using the Black-Scholes option pricing model and remeasured at each quarterly reporting date over their requisite service period. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of restricted stock grants granted to employees and non-employee directors is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The fair value of restricted stock grants granted to consultants is determined based on the closing price of our common stock on the award date, is remeasured at each quarterly reporting date and is recognized as expense ratably over the requisite service period.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Employee share-based compensation expense recognized in the three months ended March 31, 2016 and 2015 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font></font>%, based on historical forfeitures.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="27%" colspan="5"> <div style="CLEAR:both;CLEAR: both"> Three months ended March 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Research and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">29,293</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">60,735</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">152,633</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">192,633</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Restructuring benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">(53,741)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div style="CLEAR:both;CLEAR: both">Total share-based compensation expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">181,926</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">199,627</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">As a result of the restructuring and termination of employees, during the three months ended March 31, 2015, we recognized approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font> of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">129,000</font> of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">53,741</font> net reversal of share-based compensation expense is reflected in restructuring benefit in the above table.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">During the three months ended March 31, 2016, we made no stock option or restricted stock grants. During the three months ended March 31, 2015, we granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,000</font> options and made <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 117,500</font> shares of restricted stock grants to employees. At March 31, 2016, we had total unrecognized share-based compensation expense related to unvested awards of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.0</font> million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.9</font> years.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.005 Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets. Minimum payments have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases. These warrants to purchase common stock are classified as equity. These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (See Note 3 – Fair Value Measurements) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense). EX-101.SCH 7 pip-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Business and Liquidity link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Financing Transactions link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Business and Liquidity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Fair Value Measurements (Details 1) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Fair Value Measurements (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Commitments and Contingencies (Details 1) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Financing Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 pip-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pip-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pip-20160331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Billed Contracts Receivable Billed accounts receivable Unbilled Contracts Receivable Unbilled accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property and equipment, net Property and equipment, net Other Assets, Noncurrent Other long-term assets and deferred costs Goodwill Goodwill Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities [Abstract] LIABILITIES: Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Expenses And Other Current Liabilities Accrued expenses and other liabilities Accrued expenses and other liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Restructuring Reserve, Current Accrued restructuring expenses - current Other Liabilities, Current Other short-term liabilities Derivative Instruments and Hedges, Liabilities, Total Current portion of derivative instruments Liabilities, Current, Total Total current liabilities Restructuring Reserve, Noncurrent Accrued restructuring expenses - long term Other Liabilities, Noncurrent Other long-term liabilities Derivative Liability, Noncurrent Derivative instruments, less current portion Non-current portion of derivative instruments related to stock purchase warrants Liabilities, Total Total liabilities Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,444,725 and 64,382,086 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively Additional Paid in Capital, Total Additional paid-in-capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Stockholders' Equity Attributable to Parent, Total Total stockholders' equity Balance Balance Liabilities and Equity, Total Total liabilities and stockholders' equity Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Contracts Revenue Contract revenue Revenue Operating Expenses [Abstract] Operating expenses: Research and Development Expense, Total Research and development General and Administrative Expense, Total General and administrative Restructuring Charges, Total Restructuring expense Depreciation, Total Depreciation Depreciation expense Operating Expenses, Total Total operating expenses Operating Income (Loss), Total (Loss) income from operations Income (loss) from operations Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Expense, Total Interest expense, net Unrealized Gain (Loss) on Derivatives Change in fair value of derivative instruments Change in fair value of derivative instruments Unrealized (Gains) Other Nonoperating Income (Expense), Total Other income Nonoperating Income (Expense), Total Total other income Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total Net (loss) income before income taxes Income Tax Expense (Benefit) Income tax provision Income tax provision (benefit) Net Income (Loss) Attributable to Parent, Total Net (loss) income Net (loss) income Net (loss) income Net income (loss) Net income (loss) Statement of Comprehensive Income [Abstract] Earnings Per Share, Basic, Total Basic net (loss) income per share (in dollar per share) Net income (loss) per share, basic Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive (loss) income: Earnings Per Share, Diluted, Total Diluted net (loss) income per share (in dollar per share) Net income (loss) per share, diluted Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Foreign currency translation adjustments Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total Comprehensive (loss) income Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile (loss) income to net cash used in operating activities: Share-based Compensation, Total Share-based compensation expense Deferred Income Tax Expense (Benefit) Deferred income taxes Paid-in-Kind Interest Non-cash interest expense Schedule of Restructuring and Related Costs [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Gain (Loss) on Disposition of Property Plant Equipment, Total Gain on the disposal of property and equipment Restructuring Type [Axis] Increase (Decrease) in Accounts Receivable Billed accounts receivable Increase (Decrease) in Unbilled Receivables Unbilled accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable, Total Accounts payable Restructuring Reserve, Period Increase (Decrease), Total Accrued restructuring expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other liabilities Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities Billed And Unbilled Accounts Receivable Net Accounts receivable, billed and unbilled. Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Proceeds from Sale of Property, Plant, and Equipment, Total Proceeds from the sale of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities Proceeds from (Repayments of) Other Long-term Debt Repayment of debt Proceeds from (Repayments of) Lines of Credit Net repayment of revolving credit agreement Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of offering costs Proceeds from (Payments for) Other Financing Activities Other Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total Net cash provided by (used in) financing activities Effect of Exchange Rate on Cash and Cash Equivalents, Total Effects of exchange rates on cash Cash and Cash Equivalents, Period Increase (Decrease), Total Decrease in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Interest Paid, Total Cash paid for interest Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Fair Value Disclosures [Abstract] Foreign Currency Transactions and Translations Policy [Policy Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Major Customers, Policy [Policy Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Fair Value Disclosures [Text Block] Accrued Restructuring [Policy Text Block] Disclosure of accounting policy for accrued restructuring cost and related obligations. Significant Accounting Policies [Table] Type of Restructuring [Domain] Range [Axis] Share Based Compensation Extension Of Exercise Period Amount of share based compensation expense incurred during the period due to the extension of the exercise period of vested stock options. Share Based Compensation Reversal From Stock Option Forfeitures Reversal of share based compensation expense due to unvested stock options forfeited during the period. Share Based Compensation Reversal Net The net reversal amount of share based compensation due to adjustments during the period. Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Granted in Period. Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Assets, Fair Value Disclosure [Abstract] Assets Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total Investments, Fair Value Disclosure, Total Investment in money market funds Derivative Asset Total investment in money market funds Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Liabilities, Fair Value Disclosure [Abstract] Liabilities Derivative Liability, Current Current portion of derivative instruments related to stock purchase warrants Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Liability Total derivative instruments related to stock purchase warrants Beginning Balance Ending Balance Derivatives Fair Value, Hierarchy [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, by Balance Sheet Grouping [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Domain] Research and Development Expense [Member] Research and development [Member] General and Administrative Expense [Member] General and administrative [Member] Restructuring Charges [Member] Restructuring benefit [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Allocated Share-based Compensation Expense Equity Components [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Equity Component [Domain] Warrant [Member] Fair Value Measurements [Table] Fair Value Measurements [Line Items] Liability Class [Axis] Fair Value by Liability Class [Domain] Derivative Liabilities [Member] Class of Warrant or Right, Outstanding Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Derivative, by Nature [Axis] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of Common Shares Underlying Warrants Class O fWarrant Or Right Issuance Date Issue Date Class Of Warrant Or Right, Issuance Date. Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Share Based Compensation Warrants Price Range One [Member] 3.97 [Member] Share Based Compensation Warrants Price Range Two [Member] 1.63 [Member] Share Based Compensation Warrants Price Range Three [Member] 3.50 [Member] Share Based Compensation Warrants Price Range Four [Member] 1.61 [Member] Award Type [Axis] Derivative, Name [Domain] Derivative Instrument Warrants [Member] Subsequent Event Type [Axis] Equity Award [Domain] Subsequent Event Type [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Stockholders Equity [Table] Plan Name [Axis] EX-101.PRE 11 pip-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	May. 01, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Entity Registrant Name	PHARMATHENE, INC
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	PIP
Entity Common Stock, Shares Outstanding		65,591,840

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 14,235,621	$ 15,569,813
Billed accounts receivable	170,323	511,994
Unbilled accounts receivable	1,266,820	963,345
Prepaid expenses and other current assets	463,873	181,714
Total current assets	16,136,637	17,226,866
Property and equipment, net	196,143	233,694
Other long-term assets and deferred costs	53,384	53,384
Goodwill	2,348,453	2,348,453
Total assets	18,734,617	19,862,397
Current liabilities:
Accounts payable	166,357	521,122
Accrued expenses and other liabilities	1,749,899	1,248,708
Accrued restructuring expenses - current	255,551	381,950
Other short-term liabilities	0	11,250
Current portion of derivative instruments	468,304	16,411
Total current liabilities	2,640,111	2,179,441
Accrued restructuring expenses - long term	43,809	108,641
Other long-term liabilities	424,213	433,407
Derivative instruments, less current portion	0	491,791
Total liabilities	3,108,133	3,213,280
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,444,725 and 64,382,086 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	6,444	6,438
Additional paid-in-capital	240,570,971	240,366,704
Accumulated deficit	(224,950,931)	(223,724,025)
Total stockholders' equity	15,626,484	16,649,117
Total liabilities and stockholders' equity	$ 18,734,617	$ 19,862,397

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	64,444,725	64,382,086
Common stock, shares outstanding	64,444,725	64,382,086

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Contract revenue	$ 1,005,694	$ 7,068,746
Operating expenses:
Research and development	1,029,131	1,613,627
General and administrative	1,193,298	2,196,120
Restructuring expense	0	2,060,809
Depreciation	37,701	37,106
Total operating expenses	2,260,130	5,907,662
(Loss) income from operations	(1,254,436)	1,161,084
Other income (expense):
Interest expense, net	(1,050)	(25,325)
Change in fair value of derivative instruments	39,898	338,245
Other income	4,119	9,196
Total other income	42,967	322,116
Net (loss) income before income taxes	(1,211,469)	1,483,200
Income tax provision	(15,437)	(19,805)
Net (loss) income	$ (1,226,906)	$ 1,463,395
Basic net (loss) income per share (in dollar per share)	$ (0.02)	$ 0.02
Diluted net (loss) income per share (in dollar per share)	$ (0.02)	$ 0.02
Weighted average shares used in calculation of basic net (loss) income per share	64,404,396	63,633,290
Weighted average shares used in calculation of diluted net (loss) income per share	64,404,396	63,979,859

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net (loss) income	$ (1,226,906)	$ 1,463,395
Other comprehensive (loss) income:
Foreign currency translation adjustments	0	1,746
Comprehensive (loss) income	$ (1,226,906)	$ 1,465,141

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net (loss) income	$ (1,226,906)	$ 1,463,395
Adjustments to reconcile (loss) income to net cash used in operating activities:
Share-based compensation expense	181,921	199,627
Change in fair value of derivative instruments	(39,898)	(338,245)
Depreciation expense	37,701	37,106
Deferred income taxes	15,437	19,805
Non-cash interest expense	5,485	10,933
Gain on the disposal of property and equipment	0	(7,600)
Changes in operating assets and liabilities:
Billed accounts receivable	341,671	(5,863,332)
Unbilled accounts receivable	(303,475)	(296,828)
Prepaid expenses and other current assets	(282,160)	(253,779)
Accounts payable	(354,765)	146,740
Accrued restructuring expenses	(196,716)	1,938,631
Accrued expenses and other liabilities	466,563	230,186
Net cash used in operating activities	(1,355,142)	(2,713,361)
Investing activities
Purchases of property and equipment	(150)	(35,352)
Proceeds from the sale of property and equipment	0	7,600
Net cash used in investing activities	(150)	(27,752)
Financing activities
Repayment of debt	0	(249,999)
Net repayment of revolving credit agreement	0	0
Proceeds from issuance of common stock, net of offering costs	23,237	84,332
Other	(885)	0
Net cash provided by (used in) financing activities	22,352	(165,667)
Effects of exchange rates on cash	(1,252)	(11,615)
Decrease in cash and cash equivalents	(1,334,192)	(2,918,395)
Cash and cash equivalents, at beginning of period	15,569,813	18,643,351
Cash and cash equivalents, at end of period	14,235,621	15,724,956
Supplemental disclosure of cash flow information
Cash paid for interest	$ 0	$ 14,849

XML 18 R7.htm IDEA: XBRL DOCUMENT

Business and Liquidity

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 - Business and Liquidity

During 2016, we will continue to develop our plans to create shareholder value from the alternative SIGA litigation outcomes and will commence execution of those plans.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Foreign Currency Translation

Cash and Cash Equivalents

Significant Customers and Accounts Receivable

Our primary customer is NIAID. As of March 31, 2016 and December 31, 2015, the Company’s receivable balances (both billed and unbilled) were comprised solely of receivables from NIAID.

Goodwill

Accrued Restructuring Expense

Accrued restructuring expense as of March 31, 2016 is as follows:

	Balance as of						Balance as of
	December 31,		Paid		Amortized		March 31,
Description	2015		2016		2016		2016

Accrued severance expense	$	131,822	$	131,822	$	-	$	-
Accrued sublease expense		358,769		-		59,409		299,360
Total accrued restructuring expense	$	490,591	$	131,822	$	59,409	$	299,360

Fair Value of Financial Instruments

Revenue Recognition

We generate our revenue from cost-plus-fee contracts and in the past, have generated revenue from fixed price contracts.

Milestones are considered substantive if all of the following conditions are met:

•

it relates solely to past performance, and

•

the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

Collaborative Arrangements

Research and Development

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors and consultants under our stock compensation plans.

Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:

	Three months ended March 31,
	2016		2015

Research and development	$	29,293	$	60,735
General and administrative		152,633		192,633
Restructuring benefit		-		(53,741)
Total share-based compensation expense	$	181,926	$	199,627

Income Taxes

Basic and Diluted Net Loss Per Share

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Note 3 - Fair Value Measurements

•

Level 1 — Quoted prices in active markets for identical assets or liabilities.

•

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of March 31, 2016
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,434,907	$	-	$	-	$	6,434,907
Total investment in money market funds	$	6,434,907	$	-	$	-	$	6,434,907

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304
Non-current portion of derivative instruments related to stock purchase warrants		-		-		-		-
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304

	As of December 31, 2015
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,430,561	$	-	$	-	$	6,430,561
Total investment in money market funds	$	6,430,561	$	-	$	-	$	6,430,561

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	16,411	$	16,411
Non-current portion of derivative instruments related to stock purchase warrants		-		-		491,791		491,791
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	508,202	$	508,202

(1)

Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

As of March 31, 2016 the Company did not have any transfers between Level 1 and Level 2 assets.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2016 and 2015:

	Balance as of		Unrealized		Balance as of
	December 31,		(Gains)		March 31,
Description	2015		2016		2016
Derivative liabilities related to stock purchase warrants	$	508,202	$	(39,898)	$	468,304

	Balance as of		Unrealized		Balance as of
	December 31,		(Gains)		March 31,
Description	2014		2015		2015
Derivative liabilities related to stock purchase warrants	$	807,679	$	(338,245)	$	469,434

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 4 - Commitments and Contingencies

SIGA Litigation

(i)

payment in full in cash of the unpaid balance of our claim plus interest;

(ii)

delivery to us of 100% of SIGA’s common stock; or

(iii)

such other treatment as may be mutually agreed upon in writing by SIGA and PharmAthene and approved by the Bankruptcy Court.

If SIGA does not make its choice or satisfy the judgment in the manner in which it has chosen by October 19, 2016, we will receive 100% of SIGA by October 24, 2016.

Government Contracting

Registration Rights Agreements

Leases

We lease our office in Maryland under a 10 year operating lease, which commenced on May 1, 2007. Remaining annual minimum payments are as follows:

Year	Lease Payments⁽¹⁾

2016	$	640,362
2017		356,911
	$	997,273

(1)

Minimum payments have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases.

On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space at an amount less than the Company’s leased amount.

Description	Present Value at March 31, 2016
Accrued restructuring expenses - current	$	255,551
Accrued restructuring expenses - long term	$	43,809

License Agreements

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 5 - Stockholders’ Equity

Stockholder Rights Plan

Long-Term Incentive Plan

Warrants

Number of Common Shares
Underlying Warrants As of
March 31, 2016		Issue Date	Exercise Price		Expiration Date
	100,778⁽¹⁾	March 2007	$	3.97	March 2017
	903,996⁽²⁾	July 2010	$	1.63	January 2017
	371,423⁽²⁾	June 2011	$	3.50	June 2016
	46,584⁽¹⁾	March 2012	$	1.61	March 2022
	1,422,781

(1)

These warrants to purchase common stock are classified as equity.

(2)

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Financing Transactions

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Additional Financial Information Disclosure [Text Block]

Note 6 – Financing Transactions

Controlled Equity Offering

XML 24 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note 7 – Subsequent Events

XML 25 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Major Customers, Policy [Policy Text Block]

Significant Customers and Accounts Receivable

Our primary customer is NIAID. As of March 31, 2016 and December 31, 2015, the Company’s receivable balances (both billed and unbilled) were comprised solely of receivables from NIAID.

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Accrued Restructuring [Policy Text Block]

Accrued Restructuring Expense

Accrued restructuring expense as of March 31, 2016 is as follows:

	Balance as of						Balance as of
	December 31,		Paid		Amortized		March 31,
Description	2015		2016		2016		2016

Accrued severance expense	$	131,822	$	131,822	$	-	$	-
Accrued sublease expense		358,769		-		59,409		299,360
Total accrued restructuring expense	$	490,591	$	131,822	$	59,409	$	299,360

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

We generate our revenue from cost-plus-fee contracts and in the past, have generated revenue from fixed price contracts.

Milestones are considered substantive if all of the following conditions are met:

•

it relates solely to past performance, and

•

the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

Collaborative Arrangement, Accounting Policy [Policy Text Block]

Collaborative Arrangements

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees, non-employee directors and consultants under our stock compensation plans.

Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:

	Three months ended March 31,
	2016		2015

Research and development	$	29,293	$	60,735
General and administrative		152,633		192,633
Restructuring benefit		-		(53,741)
Total share-based compensation expense	$	181,926	$	199,627

Income Tax, Policy [Policy Text Block]

Income Taxes

Basic and Diluted Net Loss Per Share, policy [Policy Text Block]

Basic and Diluted Net Loss Per Share

Recent Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 26 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]

Accrued restructuring expense as of March 31, 2016 is as follows:

	Balance as of						Balance as of
	December 31,		Paid		Amortized		March 31,
Description	2015		2016		2016		2016

Accrued severance expense	$	131,822	$	131,822	$	-	$	-
Accrued sublease expense		358,769		-		59,409		299,360
Total accrued restructuring expense	$	490,591	$	131,822	$	59,409	$	299,360

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

Share-based compensation expense for the three months ended March 31, 2016 and 2015 was as follows:

	Three months ended March 31,
	2016		2015

Research and development	$	29,293	$	60,735
General and administrative		152,633		192,633
Restructuring benefit		-		(53,741)
Total share-based compensation expense	$	181,926	$	199,627

XML 27 R16.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of March 31, 2016
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,434,907	$	-	$	-	$	6,434,907
Total investment in money market funds	$	6,434,907	$	-	$	-	$	6,434,907

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304
Non-current portion of derivative instruments related to stock purchase warrants		-		-		-		-
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	468,304	$	468,304

	As of December 31, 2015
	Level 1		Level 2		Level 3		Balance

Assets
Investment in money market funds⁽¹⁾	$	6,430,561	$	-	$	-	$	6,430,561
Total investment in money market funds	$	6,430,561	$	-	$	-	$	6,430,561

Liabilities
Current portion of derivative instruments related to stock purchase warrants	$	-	$	-	$	16,411	$	16,411
Non-current portion of derivative instruments related to stock purchase warrants		-		-		491,791		491,791
Total derivative instruments related to stock purchase warrants	$	-	$	-	$	508,202	$	508,202

(1)

Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2016 and 2015:

	Balance as of		Unrealized		Balance as of
	December 31,		(Gains)		March 31,
Description	2015		2016		2016
Derivative liabilities related to stock purchase warrants	$	508,202	$	(39,898)	$	468,304

	Balance as of		Unrealized		Balance as of
	December 31,		(Gains)		March 31,
Description	2014		2015		2015
Derivative liabilities related to stock purchase warrants	$	807,679	$	(338,245)	$	469,434

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Remaining annual minimum payments are as follows:

Year	Lease Payments⁽¹⁾

2016	$	640,362
2017		356,911
	$	997,273

(1)

Minimum payments have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases.

Other Liabilities [Table Text Block]

Description	Present Value at March 31, 2016
Accrued restructuring expenses - current	$	255,551
Accrued restructuring expenses - long term	$	43,809

XML 29 R18.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

The warrants outstanding as of March 31, 2016, all of which are exercisable, were as follows:

Number of Common Shares
Underlying Warrants As of
March 31, 2016		Issue Date	Exercise Price		Expiration Date
	100,778⁽¹⁾	March 2007	$	3.97	March 2017
	903,996⁽²⁾	July 2010	$	1.63	January 2017
	371,423⁽²⁾	June 2011	$	3.50	June 2016
	46,584⁽¹⁾	March 2012	$	1.61	March 2022
	1,422,781

(1)

These warrants to purchase common stock are classified as equity.

(2)

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Business and Liquidity (Details Textual) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended
Business and Liquidity (Details Textual) - USD ($)	Apr. 30, 2016	May. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 09, 2014
Restructuring Cost and Reserve [Line Items]
Cash and Cash Equivalents, at Carrying Value, Total			$ 14,235,621	$ 15,569,813	$ 15,724,956	$ 18,643,351
Billed And Unbilled Accounts Receivable Net			1,400,000
Liabilities, Current, Total			2,640,111	$ 2,179,441
Initial Fund Value							$ 5,200,000
Additional Fund Value							$ 4,900,000
Litigation Settlement, Amount			208,000,000
Total Value Of Contracts With Government			28,100,000
SIGA Technologies Inc [Member]
Restructuring Cost and Reserve [Line Items]
Litigation Settlement, Amount			$ 208,000,000
SIGA Technologies Inc [Member] \| Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Proceeds From interest On Legal Settlement Claims	$ 900,000
Proceeds from Legal Settlements		$ 5,000,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details)	3 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2016 USD ($)
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2015	$ 490,591
Paid	131,822
Amortized	59,409
Balance as of March 31, 2016	299,360
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2015	131,822
Paid	131,822
Amortized	0
Balance as of March 31, 2016	0
Sublease Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Balance as of December 31, 2015	358,769
Paid	0
Amortized	59,409
Balance as of March 31, 2016	$ 299,360

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 181,926	$ 199,627
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	29,293	60,735
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	152,633	192,633
Restructuring benefit [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 0	$ (53,741)

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Significant Accounting Policies [Line Items]
Share Based Compensation Extension Of Exercise Period		$ 75,000
Share Based Compensation Reversal From Stock Option Forfeitures		129,000
Share Based Compensation Reversal Net		$ 53,741
Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period		117,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 1,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 10 months 24 days
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,200,000	4,900,000
Current Income Tax Expense (Benefit), Total	$ 20,000	$ 20,000
Percentage Of Share Based Compensation Forfeitures	12.00%	12.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	12,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)

Mar. 31, 2016

Dec. 31, 2015

Liabilities

Non-current portion of derivative instruments related to stock purchase warrants

$ 0

$ 491,791

Total derivative instruments related to stock purchase warrants

468,304

Fair Value, Measurements, Recurring [Member]

Assets

Investment in money market funds

^[1]

6,434,907

6,430,561

Total investment in money market funds

6,434,907

6,430,561

Liabilities

Current portion of derivative instruments related to stock purchase warrants

468,304

16,411

Non-current portion of derivative instruments related to stock purchase warrants

491,791

Total derivative instruments related to stock purchase warrants

468,304

508,202

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]

Assets

Investment in money market funds

^[1]

6,434,907

6,430,561

Total investment in money market funds

6,434,907

6,430,561

Liabilities

Current portion of derivative instruments related to stock purchase warrants

Non-current portion of derivative instruments related to stock purchase warrants

Total derivative instruments related to stock purchase warrants

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]

Assets

Investment in money market funds

^[1]

Total investment in money market funds

Liabilities

Current portion of derivative instruments related to stock purchase warrants

Non-current portion of derivative instruments related to stock purchase warrants

Total derivative instruments related to stock purchase warrants

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]

Assets

Investment in money market funds

^[1]

Total investment in money market funds

Liabilities

Current portion of derivative instruments related to stock purchase warrants

468,304

16,411

Non-current portion of derivative instruments related to stock purchase warrants

491,791

Total derivative instruments related to stock purchase warrants

$ 468,304

$ 508,202

[1]	Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 1) - USD ($)	3 Months Ended
Fair Value Measurements (Details 1) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unrealized (Gains)	$ (39,898)	$ (338,245)
Ending Balance	468,304
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning Balance	508,202	807,679
Unrealized (Gains)	(39,898)	(338,245)
Ending Balance	$ 468,304	$ 469,434

XML 36 R25.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details 2)	Mar. 31, 2016 USD ($)
Fair Value Measurements [Line Items]
Derivatives	$ 468,304

XML 37 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Textual) - shares	Mar. 31, 2016	Mar. 31, 2015
Derivative Liabilities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Class of Warrant or Right, Outstanding	1,275,419	1,775,419

XML 38 R27.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)

Mar. 31, 2016

USD ($)

^[1]

Commitment And Contingencies [Line Items]

2016

$ 640,362

2017

356,911

Operating Leases, Future Minimum Payments Due, Total

$ 997,273

[1]	Minimum payments have not been reduced by the minimum sublease rentals of $0.2 million due in the future under noncancellable subleases.

XML 39 R28.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details 1)	Mar. 31, 2016 USD ($)
Commitment And Contingencies [Line Items]
Accrued restructuring expenses - current	$ 255,551
Accrued restructuring expenses - long term	$ 43,809

XML 40 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) - USD ($)		1 Months Ended			2 Months Ended	3 Months Ended
	Apr. 13, 2016	Apr. 30, 2016	Dec. 23, 2015	Jan. 31, 2015	May. 31, 2016	Mar. 31, 2016	Oct. 24, 2016	Jul. 06, 2015	Mar. 31, 2015
Commitment And Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss				$ 113,100,000
Loss Contingency, Damages Awarded, Value				194,600,000
Litigation Settlement, Expense				$ 81,500,000
Maximum Amount Of Reimbursement								$ 210,000
Annual License Payment								$ 200,000
Warrant Expiration Date						Jan. 28, 2015
Percentage Of Common Stock Delivered						100.00%
Litigation Settlement Interest			$ 205,000,000
Government Contract Receivable, Progress Payments Offset									$ 5,800,000
Operating Lease Term						10 years
Operating Leases, Rent Expense, Sublease Rentals						$ 200,000
SIGA Technologies Inc [Member] \| Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Proceeds from Legal Settlements					$ 5,000,000
Loss Contingency, Damages Sought, Value		$ 20,000,000
Loss Contingency, Percentage Of Common Stock Receivable by Plaintiff							100.00%
Legal Settlement Claim, Interest Rate Description	The interest will be computed at a rate of 8.75%. If SIGA decides to extend the 120 day period by an additional 90 days, the interest will be computed at the Delaware judgment interest rate which is currently 6%.
Proceeds From interest On Legal Settlement Claims		$ 900,000
Group Three [Member]
Commitment And Contingencies [Line Items]
Percentage Of Aggregate Principal Amount Redemption						1.00%
Notes Payable Aggregate Principal Repayment Amount						$ 200,000
Group Four [Member]
Commitment And Contingencies [Line Items]
Percentage Of Aggregate Principal Amount Redemption						1.00%
Notes Payable Aggregate Principal Repayment Amount						$ 200,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - $ / shares

3 Months Ended

Mar. 31, 2016

Mar. 31, 2015

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants

1,422,781

1,922,781

Expiration Date

Jan. 28, 2015

3.97 [Member] | Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants

^[1]

100,778

Issue Date

Mar. 01, 2007

Exercise Price

$ 3.97

Expiration Date

Mar. 01, 2017

1.63 [Member] | Derivative Instrument Warrants [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants

^[2]

903,996

Issue Date

Jul. 01, 2010

Exercise Price

$ 1.63

Expiration Date

Jan. 01, 2017

3.50 [Member] | Derivative Instrument Warrants [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants

^[2]

371,423

Issue Date

Jun. 01, 2011

Exercise Price

$ 3.50

Expiration Date

Jun. 01, 2016

1.61 [Member] | Warrant [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of Common Shares Underlying Warrants

^[1]

46,584

Issue Date

Mar. 01, 2012

Exercise Price

$ 1.61

Expiration Date

Mar. 01, 2022

[1]	These warrants to purchase common stock are classified as equity.
[2]	These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (See Note 3 – Fair Value Measurements) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

XML 42 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - shares	3 Months Ended
Stockholders' Equity (Details Textual) - shares	Mar. 31, 2016	Nov. 25, 2015	Mar. 31, 2015	Dec. 31, 2008
Stockholders Equity [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,422,781		1,922,781
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	46,250
Beneficial Ownership Percentage Held By Affiliates		4.99%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total	186,957
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	16,900
Additional Amount to Declare Stockholder as an Acquiring Person Percentage		0.50%
2007 Long Term Incentive Plan [Member]
Stockholders Equity [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				3,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	10,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,600,000
2007 Long Term Incentive Plan [Member] \| Maximum [Member]
Stockholders Equity [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				4,600,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Financing Transactions (Details Textual) - USD ($) $ in Millions	Mar. 31, 2016	May. 23, 2014	Mar. 25, 2013
Equity Offering [Member]
Equity Offering [Line Items]
Maximum Value Of Stocks Issuable Under Stock Offering			$ 15.0
Commissions Owed To Sales Agent Expressed As Percentage Of Aggregate Gross Proceeds From Each Sale Of Shares	3.00%
Remaining Value Of Stock Issuable Under Stock Offering	$ 3.0
Amendment to the Controlled Equity Offering [Member]
Equity Offering [Line Items]
Maximum Value Of Stocks Issuable Under Stock Offering		$ 15.0

XML 44 R33.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Textual) - USD ($) $ in Millions	1 Months Ended	2 Months Ended	3 Months Ended
Subsequent Events (Details Textual) - USD ($) $ in Millions	Apr. 30, 2016	May. 31, 2016	Mar. 31, 2016
Litigation Settlement, Amount			$ 208.0
SIGA Technologies Inc [Member]
Litigation Settlement, Amount			$ 208.0
SIGA Technologies Inc [Member] \| Subsequent Event [Member]
Proceeds from Legal Settlements		$ 5.0
Proceeds From interest On Legal Settlement Claims	$ 0.9

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 62 172 1 true 24 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.pharmathene.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pharmathene.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.pharmathene.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 104 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.pharmathene.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Sheet http://www.pharmathene.com/role/CondensedConsolidatedStatementsOfComprehensiveLossIncome CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME Statements 5 false false R6.htm 106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.pharmathene.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 107 - Disclosure - Business and Liquidity Sheet http://www.pharmathene.com/role/BusinessAndLiquidity Business and Liquidity Notes 7 false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 109 - Disclosure - Fair Value Measurements Sheet http://www.pharmathene.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 110 - Disclosure - Commitments and Contingencies Sheet http://www.pharmathene.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 111 - Disclosure - Stockholders' Equity Sheet http://www.pharmathene.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 112 - Disclosure - Financing Transactions Sheet http://www.pharmathene.com/role/FinancingTransactions Financing Transactions Notes 12 false false R13.htm 113 - Disclosure - Subsequent Events Sheet http://www.pharmathene.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 114 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.pharmathene.com/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 115 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.pharmathene.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 116 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pharmathene.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.pharmathene.com/role/FairValueMeasurements 16 false false R17.htm 117 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.pharmathene.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.pharmathene.com/role/CommitmentsAndContingencies 17 false false R18.htm 118 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.pharmathene.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.pharmathene.com/role/StockholdersEquity 18 false false R19.htm 119 - Disclosure - Business and Liquidity (Details Textual) Sheet http://www.pharmathene.com/role/BusinessAndLiquidityDetailsTextual Business and Liquidity (Details Textual) Details http://www.pharmathene.com/role/BusinessAndLiquidity 19 false false R20.htm 120 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 121 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 122 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 123 - Disclosure - Fair Value Measurements (Details) Sheet http://www.pharmathene.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.pharmathene.com/role/FairValueMeasurementsTables 23 false false R24.htm 124 - Disclosure - Fair Value Measurements (Details 1) Sheet http://www.pharmathene.com/role/FairValueMeasurementsDetails1 Fair Value Measurements (Details 1) Details http://www.pharmathene.com/role/FairValueMeasurementsTables 24 false false R25.htm 125 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.pharmathene.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://www.pharmathene.com/role/FairValueMeasurementsTables 25 false false R26.htm 126 - Disclosure - Fair Value Measurements (Details Textual) Sheet http://www.pharmathene.com/role/FairValueMeasurementsDetailsTextual Fair Value Measurements (Details Textual) Details http://www.pharmathene.com/role/FairValueMeasurementsTables 26 false false R27.htm 127 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.pharmathene.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.pharmathene.com/role/CommitmentsAndContingenciesTables 27 false false R28.htm 128 - Disclosure - Commitments and Contingencies (Details 1) Sheet http://www.pharmathene.com/role/CommitmentsAndContingenciesDetails1 Commitments and Contingencies (Details 1) Details http://www.pharmathene.com/role/CommitmentsAndContingenciesTables 28 false false R29.htm 129 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.pharmathene.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.pharmathene.com/role/CommitmentsAndContingenciesTables 29 false false R30.htm 130 - Disclosure - Stockholders' Equity (Details) Sheet http://www.pharmathene.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.pharmathene.com/role/StockholdersEquityTables 30 false false R31.htm 131 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.pharmathene.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.pharmathene.com/role/StockholdersEquityTables 31 false false R32.htm 132 - Disclosure - Financing Transactions (Details Textual) Sheet http://www.pharmathene.com/role/FinancingTransactionsDetailsTextual Financing Transactions (Details Textual) Details http://www.pharmathene.com/role/FinancingTransactions 32 false false R33.htm 133 - Disclosure - Subsequent Events (Details Textual) Sheet http://www.pharmathene.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) Details http://www.pharmathene.com/role/SubsequentEvents 33 false false All Reports Book All Reports pip-20160331.xml pip-20160331.xsd pip-20160331_cal.xml pip-20160331_def.xml pip-20160331_lab.xml pip-20160331_pre.xml true true ZIP 51 0001144204-16-100010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-16-100010-xbrl.zip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end

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at March 31, 2016

Valuation Technique

Unobservable Inputs

Black-Scholes option pricing model

Expected term

Expected dividends

Anticipated volatility